Congestive heart failure is a syndrome where the heart is unable to pump an adequate amount of blood to meet the body's needs. It is caused by any interference with the normal mechanisms regulating cardiac output. Common causes include hypertension, myocardial infarction, and valvular disorders. The main goals of treatment are to improve left ventricular function by decreasing preload and afterload, improving gas exchange, and enhancing cardiac contractility. Management involves diuretics, vasodilators, and other medications alongside lifestyle modifications like sodium and fluid restrictions.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
2. Congestive Heart Failure
Definition
• Impaired cardiac pumping such that
heart is unable to pump adequate amount
of blood to meet metabolic needs
• Not a disease but a “syndrome”
• Associated with long-standing HTN and
CAD
4. Factors Affecting Cardiac Output
• Heart Rate
– In general, the higher the heart rate, the lower
the cardiac
• E.g. HR x SV = CO
» 60/min x 80 ml = 4800 ml/min (4.8 L/min)
» 70/min x 80 ml = 5600 ml/min (5.6 L/min)
– But only up to a point. With excessively high
heart rates, diastolic filling time begins to fall,
thus causing stroke volume and thus CO to fall
6. Factors Affecting Cardiac Output
• Preload
– The volume of blood/amount of fiber stretch
in the ventricles at the end of diastole (i.e.,
before the next contraction)
7. Factors Affecting Cardiac Output
• Preload increases with:
• Fluid volume increases
• Vasoconstriction (“squeezes” blood from
vascular system into heart)
• Preload decreases with
• Fluid volume losses
• Vasodilation (able to “hold” more blood, therefore
less returning toheart)
8. Factors Affecting Cardiac Output
• Starling’s Law
– Describes the relationship between preload and cardiac
output
– The greater the heart muscle fibers are stretched (b/c of
increases in volume), the greater their subsequentforce
of contraction – but only up to a point. Beyond that
point, fibers get over-stretched and the force of
contraction is reduced
• Excessive preload = excessive stretch → reduced
contraction → reduced SV/CO
10. Factors Affecting Cardiac Output
• Afterload
– The resistance against which the ventricle must
pump. Excessive afterload = difficult to pump
blood → reduced CO/SV
– Afterload increased with:
• Hypertension
• Vasoconstriction
– Afterload decreased with:
• Vasodilation
11. Factors Affecting Cardiac Output
• Contractility
– Ability of the heart muscle to contract; relates
to the strength of contraction.
12. Factors Affecting Cardiac Output
• Contractility decreased with:
– infarcted tissue – no contractile strength
– ischemic tissue – reduced contractile strength.
– Electrolyte/acid-base imbalance
– Negative inotropes (medications that decrease
contractility, such as beta blockers).
• Contractility increased with:
– Sympathetic stimulation (effects of epinephrine)
– Positive inotropes (medications that increase
contractility, such as digoxin, sympathomimmetics)
13. Pathophysiology of CHF
• Pump fails → decreased stroke volume /CO.
• Compensatory mechanisms kick in to increase CO
– SNS stimulation → release of epinephrine/nor-
epinephrine
• Increase HR
• Increase contractility
• Peripheral vasoconstriction (increases afterload)
– Myocardial hypertrophy: walls of heart thicken to
provide more muscle mass → stronger contractions
14. Pathophysiology of CHF
– Hormonal response: ↓’d renal perfusion
interpreted by juxtaglomerular apparatus as
hypovolemia. Thus:
• Kidneys release renin, which stimulates
conversion of antiotensin I → angiotensin
II, which causes:
– Aldosterone release → Na retention and
water retention (via ADH secretion)
– Peripheral vasoconstriction
15. Pathophysiology of CHF
• Compensatory mechanisms may restore
CO to near-normal.
• But, if excessive the compensatory
mechanisms can worsen heart failure
because . . .
16. Pathophysiology of CHF
• Vasoconstriction: ↑’s the resistance against
which heart has to pump (i.e., ↑’s afterload), and
may therefore ↓ CO
• Na and water retention: ↑’s fluid volume, which
↑’s preload. If too much “stretch” (d/t too much
fluid) → ↓ strength of contraction and ↓’s CO
• Excessive tachycardia → ↓’d diastolic filling
time → ↓’d ventricular filling → ↓’d SV and CO
18. Congestive Heart Failure
Etiology
• May be caused by any interference with
normal mechanisms regulating cardiac
output (CO)
• Common causes
– HTN
– Myocardial infarction
– Dysrhythmias
– Valvular disorders
19. Congestive Heart Failure
Types of Congestive Heart Failure
• Left-sided failure
– Most common form
– Blood backs up through the left atrium
into the pulmonary veins
• Pulmonary congestion and edema
– Eventually leads to biventricular failure
20. Congestive Heart Failure
Types of Congestive Heart Failure
• Left-sided failure
– Most common cause:
• HTN
• Cardiomyopathy
• Valvular disorders
• CAD (myocardial infarction)
21. Congestive Heart Failure
Types of Congestive Heart Failure
• Right-sided failure
– Results from diseased right ventricle
– Blood backs up into right atrium and
venous circulation
– Causes
• LVF
• Cor pulmonale
• RV infarction
28. Congestive Heart Failure
Classification
• Based on the person’s tolerance to physical
activity
– Class 1: No limitation of physical activity
– Class 2: Slight limitation
– Class 3: Marked limitation
– Class 4: Inability to carry on any physical
activity without discomfort
29. Congestive Heart Failure
Diagnostic Studies
• Primary goal is to determine underlying
cause
– Physical exam
– Chest x-ray
– ECG
– Hemodynamic assessment
30. Congestive Heart Failure
Diagnostic Studies
• Primary goal is to determine underlying
cause
– Echocardiogram (Uses ultrasound to visualize
myocardial structures and movement, calculate EF)
– Cardiac catheterization
31. Acute Congestive Heart Failure
Nursing and Collaborative
Management
• Primary goal is to improve LV function by:
– Decreasing intravascular volume
– Decreasing venous return
– Decreasing afterload
– Improving gas exchange and oxygenation
– Improving cardiac function
– Reducing anxiety
32. Acute Congestive Heart Failure
Nursing and Collaborative
Management
• Decreasing intravascular volume
– Improves LV function by reducing
venous return
– Loop diuretic: drug of choice
– Reduces preload
– High Fowler’s position
34. Acute Congestive Heart Failure
Nursing and Collaborative
Management
• Improving cardiac function
– Positive inotropes
• Improving gas exchange and oxygenation
– Administer oxygen, sometimes intubate and
ventilate
• Reducing anxiety
– Morphine
35. Chronic Congestive Heart Failure
Collaborative Care
• Treat underlying cause
• Maximize CO
• Alleviate symptoms
38. Chronic Congestive Heart Failure
Nutritional Therapy
• Fluid restrictions not commonly prescribed
• Sodium restriction
– 2 g sodium diet
• Daily weights
– Same time each day
– Wearing same type of clothing
39. Chronic Congestive Heart Failure
Nursing Management
Nursing Assessment
• Past health history
• Medications
• Functional health problems
• Cold, diaphoretic skin
42. Chronic Congestive Heart Failure
Nursing Management
Planning
• Overall goals:
– Peripheral edema
– Shortness of breath
– Exercise tolerance
– Drug compliance
– No complications
43. Chronic Congestive Heart Failure
Nursing Management
Nursing Implementation
• Acute intervention
– Establishment of quality of life goals
– Symptom management
– Conservation of physical/emotional energy
– Support systems are essential